Bristol-Myers Squibb Drug Pipeline

Bristol-Myers Squibb maintains a substantial clinical portfolio, with 147 active trials out of 1254 total trials registered since 2008. These active programs span from Phase 1 through Phase 4, with 46, 53, 74, and 7 trials respectively. The portfolio covers 11 therapeutic areas, but is heavily concentrated in Oncology, which accounts for 70% of active programs (103 trials). Central nervous system (CNS) and Immunology are the next most active areas, with 20 and 16 active trials, respectively. Within Oncology, the most active indications are Solid Tumor (Advanced) with 15 active trials including 4 in Phase 3, Non-Small Cell Lung Cancer (NSCLC) with 13 active trials including 7 in Phase 3, Multiple Myeloma with 10 active trials including 6 in Phase 3, Non-Hodgkin Lymphoma with 9 active trials including 3 in Phase 3, and Melanoma with 6 active trials including 3 in Phase 3. The significant number of Phase 3 trials across multiple Oncology indications suggests a potential for near-term clinical catalysts.